TNF and COVID-19: As far as we know, there are no RCTs on the use of anti-TNF in severe COVID-19, and our knowledge derives from indirect observations of patients who are on anti-TNF drugs for underlying comorbidities and who contract SARS-CoV-2 infection; observational studies suggest that those patients tend to have a better outcome [59,60].